Abstract:Atherosclerosis-induced cardiovascular diseases (CVDs) are accompanied by substantial morbidity and mortality. The loss and injury of endothelial cells is the primary cause of atherosclerosis. Rosuvastatin is an alternative agent used to reduce the risk of cardiovascular disease. Subsequently, the present study aimed to investigate the protective effects of rosuvastatin on oxidized-low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cell (HUVEC) injury. The viability of ox-LDL-cultured HUVECs with or without rosuvastatin (0.01, 0.1 and 1 mu mol/l) pretreatment, and pretreatment at different time points (3, 6, 12 and 24 h) was determined using an MTT assay. Morphological changes and the extent of apoptosis were detected; the anti-oxidase activity, including superoxide dismutase (SOD) and catalase (CAT), was examined, and the contents of malondiahdehyde (MDA) and nitric oxide (NO) were measured. The phosphorylation levels of endothelial nitric oxide synthase (eNOS), protein kinase B (Akt) and phosphoinositide 3 kinase (PI3K) were detected using western blot analysis. The results demonstrated that pretreatment with 0.01-1 mu mol/l rosuvastatin decreased cell apoptosis caused by ox-LDL. Notably, pretreatment with 1 mu mol/l rosuvastatin for >12 h increased cell viability. Additionally, DAPI staining revealed that rosuvastatin inhibited HUVEC apoptosis. Rosuvastatin treatment also resulted in increased SOD and CAT activities and decreased MDA content in ox-LDL-stimulated HUVECs. Furthermore, pretreatment with 0.01-1 mu mol/l rosuvastatin significantly increased` the NO content compared with HUVECs treated with ox-LDL alone. Western blot analyses demonstrated that rosuvastatin upregulated the phosphorylation of eNOS, Akt and PI3K. These findings indicated that rosuvastatin could protect HUVECs against ox-LDL-induced injury through its anti-oxidant effect and its ability to upregulate the expression of vascular endotheliocyte-protecting factors.

Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

A new HMG-CoA reductase inhibitor: rosuvastatin

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Comparison of efficacy of rosuvastatin and artovastatin in treatment of hypercholesterolemia

An Evaluation Of Pitavastatin For The Treatment Of Hypercholesterolemia

Efficacy and Safety of Rosuvastatin Versus Atorvastatin in High-Risk Chinese Patients with Hypercholesterolemia: a Randomized, Double-Blind, Active-Controlled Study

Current clinic researches of rosuvastain

Study on pharmacokinetics of rosuvastatin and its drug interactions with other drugs

Clinical Interventions in Aging Dovepress Managing Hypercholesterolemia and Preventing Cardiovascular Events in Elderly and Younger Chinese Adults: Focus on Rosuvastatin

Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia

Efficacy and safety of rosuvastatin in the treatment of hypercholesterolemia

Efficacy and Safety of Rosuvastatin Vs. Atorvastatin in Lowering LDL Cholesterol

Rosuvastatin effects on the HDL proteome in hyperlipidemic patients

Managing Hypercholesterolemia and Preventing Cardiovascular Events in Elderly and Younger Chinese Adults: Focus on Rosuvastatin

The Efficacy and Safety of Rosuvastatin Calcium Tablets for Treatment of Hyperlipidemia

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Protection of renal damage by HMG-CoA inhibitors: A comparative study between atorvastatin and rosuvastatin

Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.

Rosuvastatin protects against oxidized low‑density lipoprotein‑induced endothelial cell injury of atherosclerosis in vitro.

Rosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of alpha-1-antitrypsin Enriched Particles with Anti-inflammatory Properties